PsA screening in those with psoriasis could save $220 million annually

If early therapy with DMARDs can slow disease progression and delay expensive biologic treatment, early screening for psoriatic arthritis among patients with psoriasis could save $220 million each year in Canada and improve quality of life, according to data published in Arthritis Care & Research.“The cost and health burden of PsA is considerable,” Nicolas Iragorri, MSc, of the

Read the full article here

Related Articles